Share your videos with the world

Sign Up | Log In | Help  

   
 
Related Tags: fda  brain  cancer  health  healthcare  treatment  medicine  glioma  multivu  7944251  health  safety  healthcare  shooter  threat  preparation  emergency  security  mhsda  multivu  7883351  kia  cadenza  car  auto  new  york  international  auto  show  technology  consumers  multivu  7731856  cvs  health  pharmacy  medication  tobacco  free  medical  disease  children  multivu  7775151  cancer  miracle  health  research  diagnosed  treatments  medicine  therapies  multivu  7665051  leukemia  lymphoma  society  health  medical  therapy  research  cancer  treatments  disease  multivu  7554852  mens  health  network  joe  torre  prostate  cancer  awareness  multivu  7322251  national  mining  association  epa  regulations  electricity  utility  coal  power  plant  energy  politics  multivu  7221751  kia  motors  america  gt4  stinger  concept  sports  cars  2014  naias  auto  show  vehicles  multivu  65141  leukemia  cancer  childrens  hospital  philadelphia  chop  cell  therapy  immunotherapy  treatment  research  multivu  64394  chop  childhood  cancer  advanced  leukemia  relapsed  patients  cell  therapy  treatment  research  multivu  50777  childrens  hospital  philadelphia  lymphoma  neuroblastoma  cancer  medication  treatment  genes  therapy  health  multivu  50776 
Search // aggressive
Results 1-12 of 15 for ' aggressive ' (0 seconds)
A first-of-a-kind neural stem cell therapy that works with a common cold virus to seek out and attack a lethal and aggressive brain cancer is being tested at Northwestern Medicine in a Phase I clinical trial for patients newly diagnosed with malignant glioma. The novel drug to treat malignant glioma, notorious for recurring after typical bouts of standard cancer treatment, was developed by a Northwestern scientist and has been approved as an investigational drug by the U.S. Food and Drug Administration. This is only the second time the University has supported and filed an investigational new drug as a sponsor. To view the multimedia release go to: https://www.multivu.com/players/English/7944251-northwestern-medicine-stem-cell-trial/
Categories // Miscellaneous 
Added: 2471 days ago by MultiVuVideos
Runtime: 4m28s | Views: 562 | Comments: 1
Not yet rated
 

 

 

Allied Universal, a leading facility services company and the largest security force in North America, together with John Jay College and the Metropolitan Healthcare Security Directors Association (MHSDA), will host a “Plan to Live” seminar to educate healthcare providers on best practices to handle an active shooter situation and other threats. The free seminar will be held Tues., May 16, from 9 a.m. to 1:30 p.m. in the college’s Moot Court at 899 10th Avenue, New York City. “Active shooters are not the only risks that healthcare facilities face,” said Kevin Francis, Business Development Specialist, Allied Universal. “Healthcare facilities may encounter aggressive assailants, bomb threats, and terrorist attacks. Our seminar provides tips and information from leading experts to help them prepare for, survive and recover from an attack.” To view the multimedia release go to: https://www.multivu.com/players/English/7883351-allied-universal-john-jay-active-shooter-seminar/
Categories // Miscellaneous 
Added: 2515 days ago by MultiVuVideos
Runtime: 3m1s | Views: 538 | Comments: 0
Not yet rated
 

 

 

Imagine being diagnosed with one of the most rare and aggressive forms of breast cancer, given a five percent chance to live and told having children will never be an option. Southern California local Kommah McDowell was told just that— and then she went to City of Hope. It is estimated that almost 40 percent of men and women in the U.S. will be diagnosed with cancer sometime during their lifetime. Kommah, who was diagnosed at age 29, now has her health and her son, thanks to discoveries made at City of Hope, where scientists and doctors turn laboratory breakthroughs into treatments that defeat cancer. Today, the nonprofit research and comprehensive cancer center near Los Angeles is rolling out a new initiative that builds on its legacy of discovery to let people know that City of Hope not only offers a uniquely patient-centric, integrated approach to care, but also with the help of donors and volunteers, it is pursuing research that will change the future of medicine. To view the multimedia release go to: http://www.multivu.com/players/English/7665051-city-of-hope-miracle-science-soul-campaign/
Categories // Miscellaneous 
Added: 3081 days ago by MultiVuVideos
Runtime: 1m45s | Views: 719 | Comments: 0
Not yet rated
 

 

 

The Leukemia & Lymphoma Society (LLS) today announced it has committed $28.6 million in new research investment to advance the most promising blood cancer science at leading academic and medical institutions around the world, including Dana-Farber Cancer Institute, Weill Cornell Medical College and MD Anderson Cancer Center. As LLS leads the charge to find cures for cancer patients, this new funding, along with ongoing investment in LLS’s aggressive research agenda, brings LLS’s total commitment to blood cancer research to more than $1 billion. The investment has led to the development of nearly every therapy currently used to treat the blood cancers. Along with these new research grants, LLS remains committed to collaborating with biotechnology companies through its innovative Therapy Acceleration Program® (TAP), a model pioneered by LLS in the cancer arena in recognition that traditional research approaches weren’t yielding treatments and cures fast enough for patients. LLS commits approximately $13 million a year to its TAP initiatives. As part of the 24 current such collaborations, LLS recently initiated new investments with Kite Pharma and OncoPep. To view the multimedia release go to: http://www.multivu.com/players/English/7554852-lls-cancer-research-funding/
Categories // Miscellaneous 
Added: 3102 days ago by MultiVuVideos
Runtime: 1m4s | Views: 762 | Comments: 0
Not yet rated
 

 

 

In partnership with Men’s Health Network (MHN), Prostate Health Education Network (PHEN), ZERO – the End of Prostate Cancer and Joe Torre, four-time world champion baseball Hall-of-Famer and prostate cancer survivor, Genomic Health, Inc. (Nasdaq: GHDX) today launched Your Prostate Your Decision to educate prostate cancer patients and their loved ones that every man is different and every cancer is unique, and a genomic test can clarify the aggressiveness of one’s disease prior to invasive treatment. This first-of-its-kind national effort aims to address concerning results of a large national survey that found low general awareness about prostate cancer aggressiveness and treatment options, underscoring the need for better understanding of active surveillance as a treatment plan. “For a man with prostate cancer, a single decision can change his entire life,” said Mr. Torre, reflecting on his own experience with prostate cancer. “When I was diagnosed with prostate cancer, I faced a game-changing decision. While I chose surgery, a less aggressive approach called active surveillance might be the best choice.” To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7322251-your-prostate-your-decision-joe-torre-talks-about-prostate-cancer-genomic-testing-treatment-options-psa/
Categories // Miscellaneous 
Added: 3473 days ago by MultiVuVideos
Runtime: 1m0s | Views: 970 | Comments: 0
Not yet rated
 

 

 

The National Mining Association (NMA) called on policymakers to reject an ill-conceived administration proposal that would jeopardize America’s electric grid and threaten the economic well-being of consumers and businesses. Recently, the Environmental Protection Agency’s (EPA) proposed aggressive guidelines for regulating greenhouse gas emissions from existing coal-based power plants that generate 40 percent of the nation’s electricity and which will raise the cost of electricity for all Americans, according to NMA. To view the Multimedia News Release, go to http://www.multivu.com/players/English/7221751-national-mining-association-affordable-reliable-electricity/
Categories // Business  News and Politics 
Added: 3577 days ago by MultiVuVideos
Runtime: 2m29s | Views: 774 | Comments: 2
Not yet rated
 

 

 

Hearkening back to the glory days of purebred, affordable sports cars, Kia Motors America (KMA) today unveiled the brand’s most aggressive concept car ever when wraps came off the GT4 Stinger at the North American International Auto Show (NAIAS). Kia’s eye-catching design language moves in a bold new direction with the introduction of the GT4 Stinger. The concept pushes the boundaries of performance with a rear-drive 2+2 sports car that places man and machine in harmony on the road or track. It comes as no surprise that the GT4 Stinger is the wild style child of Kia’s California design team, home to its 2012 predecessor, the Track’ster concept. And like the Track’ster, the GT4 Stinger’s racy appeal is more than skin deep. To view the Multimedia News Release, go to http://www.multivu.com/mnr/65141-kia-shocks-the-motor-city-rear-drive-gt4-stinger-2014-naias
Categories // Cars and Vehicles 
Added: 3727 days ago by MultiVuVideos
Runtime: 3m32s | Views: 1815 | Comments: 2
Not yet rated
 

 

 

Nearly 90 percent of children and adults with a highly aggressive form of acute lymphoblastic leukemia (ALL) showed no evidence of cancer after receiving a novel, personalized cell therapy that reprograms a patient’s immune system. In pilot studies of bioengineered T cells that attack leukemia, 24 of 27 patients (89%) experienced complete responses within 28 days after treatment. In all, 27 patients received the treatment--22 children treated at The Children’s Hospital of Philadelphia and five adults treated at the Hospital of the University of Pennsylvania. To view the Multimedia News Release, go to http://www.multivu.com/mnr/64394-chop-penn-harness-engineered-t-cells-eliminate-tumors-in-blood-leukemia
Added: 3762 days ago by MultiVuVideos
Runtime: 8m31s | Views: 1451 | Comments: 1
Not yet rated
 

 

 

By reprogramming a 7–year–old girl’s own immune cells to attack an aggressive form of childhood leukemia, a pediatric oncologist has achieved a complete response in his patient, who faced grim prospects when she relapsed after conventional treatment. The innovative experimental therapy used bioengineered T cells, custom–designed to multiply rapidly in the patient, and then destroy leukemia cells. After the treatment, the child’s doctors found that she had no evidence of cancer. To view Multimedia News Release, go to http://www.multivu.com/mnr/50777-chop-engineered-immune-t-cell-therapy-anticancer-effect-in-children
Added: 4126 days ago by MultiVuVideos
Runtime: 6m45s | Views: 1338 | Comments: 0
     
 

 

 

A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma. A phase 1 clinical trial of the drug crizotinib achieved remissions, with minimal side effects, for 10 of the children participating in a clinical study carried out by the multicenter Children’s Oncology Group (COG). The results were “an exciting proof-of-principle” for the targeted treatment, said the study leader, Yaël P. Mossé, M.D., a pediatric oncologist at The Children’s Hospital of Philadelphia. “We are entering a new era of cancer therapy, in which we use knowledge of basic biology to design very specific drugs that target cancer cells with potentially less side effects on healthy tissue,” said Mossé. “In addition, as we concentrate on targets in molecular pathways, we move away from an exclusive focus on one form of cancer to customizing treatments according to biological activity. Abnormal ALK activity occurs in subtypes of neuroblastoma and subtypes of lymphoma, so identifying ALK activity in individual patients may enable us to provide the most effective care.” To view Multimedia News Release, go to http://www.multivu.com/mnr/50776-childrens-hospital-philadelphia-lymphoma-neuroblastoma-oncology-gene-trial
Categories // People and Blog 
Added: 4333 days ago by MultiVuVideo
Runtime: 4m41s | Views: 4475 | Comments: 0
Not yet rated
 

 

 

Imagine a device worn on your finger that allows intuitive, touch-free interaction with the digital world. Imagine a solar panel the size of a microcontroller that enables environmental intelligence in any building. Imagine integrating carbon monoxide sensing, thermostat control and biometric security capabilities to a smoke detector without increasing its size. This smarter, greener, battery-free world is fast becoming a reality with the world’s lowest-power microcontroller platform from Texas Instruments Incorporated (TI) (NASDAQ: TXN). Codenamed “Wolverine” for its aggressive power-saving technology, this ultra-low-power MSP430 microcontroller platform offers at least 50 percent less power consumption than any other microcontroller in the industry (360 nA real-time clock mode and less than 100 µA/MHz active power consumption). The first devices based on this platform will be the MSP430FR58xx microcontroller series with expected availability in June 2012. To view Multimedia News Release, go to http://www.multivu.com/mnr/54041-texas-instruments-ti-wolverine-microcontroller-platform
Categories // Science and Technology 
Added: 4412 days ago by MultiVuVideos
Runtime: 2m44s | Views: 7195 | Comments: 0
Not yet rated
 

 

 

New findings from the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project (PCGP) have helped identify the mechanism that makes the childhood eye tumor retinoblastoma so aggressive. The discovery explains why the tumor develops so rapidly while other cancers can take years or even decades to form. The finding also led investigators to a new treatment target and possible therapy for the rare childhood tumor of the retina, the light-sensing tissue at the back of the eye. The study appears in the January 11 advance online edition of the scientific journal Nature. To view Multimedia News Release, go to http://www.multivu.com/mnr/46767-st-jude-genome-project-treatment-childhood-eye-tumor-retinoblastoma
Categories // News and Politics 
Added: 4452 days ago by MultiVuVideos
Runtime: 5m1s | Views: 4081 | Comments: 0
Not yet rated
 

 

 

Page 1 of 2  |  Go to page    Next» LAST»»



About Us   |   Help  |   Advertise on ClipMoon   |   Terms of Use   |   Privacy Policy   |   Copyright   |   Contact   |   Link us   |   RSS 
Copyright © 2007-2024 ClipMoon.com. All rights reserved.